LEO Pharma is set to acquire exclusive global rights to dersimelagon (MT-7117), an investigational therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), from Tanabe Pharma. As part of the deal announced Tuesday, LEO will pay Tanabe $435 million in upfront and near-term milestone payments, with the latter also eligible for additional downstream milestones, alongside tiered sales royalties. Dersimelagon is a once-daily, oral melanocortin 1 receptor (MC1R) agonist des

Shares in Amylyx Pharmaceuticals jumped more than 30% on Tuesday after the company reported that a Phase III study of avexitide in people with post-bariatric hypoglycaemia (PBH) met its primary endpoint, setting up an FDA filing for the GLP-1 receptor antagonist by the end of the year. "Together with the positive data generated across five previous clinical trials of avexitide in PBH, we believe the LUCIDITY results bring us one step closer to potentially delivering the first approved treatment

AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome payload-specific resistance Results strengthen the rationale for a differentiated ADC sequencing strategy as ADC use expands across oncology and more patients require treatment following relapse Akari advancing IND-enabling activities for AKTX-101 toward planned Phase 1 clinical d

CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor 18 August 2026 -- CHARM Therapeutics (“CHARM”, “The Company”), a biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, announces the formation of its Clinical Advisory Board to support the advancement of CHM-029 into clinical studies for AML, an aggressive cancer of the blood and bone marrow. The Cli

Phase 1b/2a clinical trial assessing safety and efficacy of LTX-001 in adults with schizophrenia initiated Financing advances LTX-001 through initial readout from Phase 1b/2a trial and progresses LTX-002 through additional dosing cohorts of ongoing Phase 1/2 trial in ALS Aug. 17, 2026 -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced a second close of $30 million of its Series A financing. The ro

— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — Aug. 17, 2026 -- OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced dosing of the first patient following the clearance of the Investigational New Drug (IND) application for a

argenx said Monday the subcutaneous (SC) version of its human IgG1 antibody fragment Vyvgart (efgartigimod alfa), marketed as Vyvgart Hytrulo, cleared a Phase III trial in adults with autoimmune myositis. "For decades, people living with autoimmune myositis have relied on corticosteroids and broad immunosuppression," said Luc Truyen, chief medical officer of argenx, noting that "precision targeting of FcRn with [Vyvgart] can deliver meaningful benefit in this disease." The late-stage portion o

Aizen Therapeutics inked a multi-programme collaboration with an undisclosed, publicly listed San Diego-based biotech to design oral peptide therapeutics. The deal, announced over the weekend, grants Aizen several million in initial revenue, alongside milestone payments of up to $100 million for each chosen target. The latest partnership will employ Aizen's DaX foundation model to develop oral peptides targeting conditions across immunology and neurology. According to the AI-native firm, DaX —

Otsuka Pharmaceuticals’ Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics’ Trutakna, which the FDA granted accelerated approval last month, showed “impressive” stabilization, analysts say. In June, Otsuka Pharmaceuticals touted data suggesting its IgA nephropathy drug Voyxact could slow the decline of kidney function in patients—a unique benefit, analysts said at the time. Now, Vera Therapeutics seems to have taken that distinguishing a

Multi-program deal with revenue potential of $100 million per target Aug. 15, 2026 -- Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to design oral peptide therapeutics using its DaX™ foundation model. The agreement provides Aizen with several million dollars in initial revenue and up to $100 million in milestones for each nominated target. "Oral biologics represent